■偏头痛是一种普遍的头痛疾病,对生活质量有重大影响。本研究旨在调查erenumab的有效性和安全性,单克隆抗体靶向CGRP受体,在临床实践中治疗慢性(CM)和发作性(EM)偏头痛科威特,为治疗方案提供特定区域的见解。
■这是一项对被诊断为EM或CM的患者进行的前瞻性观察性队列研究。该研究的主要结果是评估每月平均偏头痛天数减少≥50%的患者比例。以及几个变化,包括每月偏头痛的平均天数,镇痛药的使用频率,攻击严重性,AEs,和QoL。
■该研究包括151名患者,平均年龄为44.0±11.4岁,81.9%为女性。74.2%的患者获得了主要结果,头痛频率显着降低(p<0.001),疼痛严重程度,镇痛药的使用,和QoL的改善。年龄和偏头痛持续时间是治疗后头痛频率降低≥50%的显著预测因素(OR=0.955;p=0.009)和(OR=0.965;p=0.025)。分别。76.2%的患者出现治疗依从性,24.5%停止治疗。便秘是最常见的不良事件(6.0%),保守管理是最常见的AE管理方法。
■Erenumab可有效降低偏头痛发作的频率和严重程度,并改善QoL,在科威特的现实环境中,安全且可管理的AE。需要进一步的研究来更好地了解erenumab在不同人群和环境中的有效性和安全性。以及将其与其他偏头痛预防性治疗方法进行比较。
UNASSIGNED: Migraine is a prevalent headache disorder with a significant impact on the quality of life. This study aims to investigate the effectiveness and safety of erenumab, mAb targeting the CGRP receptor, in treating chronic (CM) and episodic (EM) migraine in clinical practice Kuwait, providing region-specific insights to treatment options.
UNASSIGNED: This was a prospective observational cohort study of patients diagnosed with EM or CM treated with erenumab. The primary outcome of the study was to assess the proportion of patients achieving ≥ 50% reduction in monthly mean migraine days, and several changes including the mean number of monthly migraine days, the frequency of analgesic use, attack severity, AEs, and QoL.
UNASSIGNED: The study included 151 patients with a mean age of 44.0±11.4 years, and 81.9% female. The primary outcome was achieved in 74.2% of patients, with a significant (p < 0.001) reduction in headache frequency, pain severity, analgesic use, and improvement in QoL. Age and duration of migraine were significant predictors of achieving a ≥ 50% reduction in headache frequency after therapy (OR = 0.955; p = 0.009) and (OR = 0.965; p = 0.025), respectively. Treatment compliance was observed in 76.2% of patients, and 24.5% discontinued treatment. Constipation was the most commonly reported AEs (6.0%), and conservative management was the most common approach to managing AEs.
UNASSIGNED: Erenumab was effective in reducing the frequency and severity of migraine attacks and improving QoL, and safe with manageable AEs in a real-world setting in Kuwait. Further research is needed to better understand erenumab\'s effectiveness and safety in different populations and settings, as well as to compare it with other migraine prophylactic treatments.